Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
POS AM
Prospectus update (post-effective amendment)
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 24
8-K
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
S-8
Registration of securities for employees
12 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
7 Nov 23
8-K
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
31 Oct 23
8-K
Regulation FD Disclosure
12 Sep 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8 Aug 23
8-K
Results of Operations and Financial Condition
27 Jul 23
8-K
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
15 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
9 Jun 23
S-3ASR
Automatic shelf registration
9 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
31 Mar 23
8-K
Entry into a Material Definitive Agreement
24 Mar 23
8-K
Mersana Therapeutics Provides Statement About SVB
13 Mar 23
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
28 Feb 23
8-K
Company plans to report interim data for the combination of UpRi with carboplatin in the second half of 2023
1 Feb 23
8-K
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
25 Jan 23
8-K
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
6 Jan 23
8-K
Entry into a Material Definitive Agreement
27 Dec 22
8-K
Entry into a Material Definitive Agreement
22 Dec 22
Latest ownership filings
4
Lawrence M Alleva
3 Apr 24
4/A
Ashish Mandelia
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G
BALYASNY ASSET MANAGEMENT L.P.
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
Anna Protopapas
17 Jan 24
4
TUSHAR MISRA
17 Jan 24
4
Ashish Mandelia
17 Jan 24
4
Timothy B Lowinger
17 Jan 24
4
Martin H. Jr. Huber
17 Jan 24
4
Alejandra Carvajal
17 Jan 24
4
Brian DeSchuytner
17 Jan 24
4
Mohan Bala
17 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
4
Lawrence M Alleva
4 Jan 24
4
Kristen Hege
4 Jan 24
4
Willard H Dere
4 Jan 24
4
DAVID M MOTT
4 Jan 24
4
Mohan Bala
27 Oct 23
4
Martin H. Jr. Huber
4 Oct 23
4
Willard H Dere
4 Oct 23
4
Kristen Hege
4 Oct 23
4
Lawrence M Alleva
4 Oct 23
4
DAVID M MOTT
4 Oct 23
4
Anna Protopapas
13 Sep 23
4
Martin H. Jr. Huber
13 Sep 23
4
Alejandra Carvajal
7 Sep 23
4
Timothy B Lowinger
7 Sep 23
4
Ashish Mandelia
7 Sep 23
4
TUSHAR MISRA
7 Sep 23
4
Brian DeSchuytner
7 Sep 23
3
Mohan Bala
7 Sep 23